top of page

Awareness session organized by MATWIN and Cancer Campus - September 20 and 21, 2018 in Paris


Optimizing the maturation of an innovation in oncology : from research to the early clinic


INTRODUCTION


Despite the progress made in recent years, cancer remains a major cause of morbidity and mortality. The search for new diagnostic tools, medical devices or anti-cancer drugs is, therefore, very active. It is estimated that more than 900 new molecules are currently under development worldwide. Academic researchers wishing to pursue their work to proof of concept and towards industrial and clinical transfer are therefore faced with new and specific development challenges.


MATWIN and Cancer Campus are therefore offering a one-day "awareness-raising" training course to project leaders in oncology innovation that will enable them to identify the main challenges, constraints and key success factors in the development of an innovation in oncology (therapy, diagnosis or medical device) from research to early clinical development through various themes (preclinical framework and proof of concept, development plan, project management, sources of funding, fundraising, patent strategy, regulatory framework, etc.), all based on a series of presentations. ), all based on concrete examples.

PROGRAM


DATE - LOCATION

September 20 and 21, 2018

Place: Chimie ParisTech - École nationale supérieure de chimie de Paris - 11, rue Pierre et Marie Curie PARIS 5ème

PARTICIPANTS

Any project leader developing an innovation with an application in oncology (therapeutic, diagnostic or DM): academic researchers, clinicians, start-ups, PhD students...

Registration in progress

Please note: access to the session is reserved for a maximum of 40 participants.

COST

Free for candidates who apply to MATWIN or OncoEntrepreneur (2018-2019 edition)

50€ HT (includes availability of the venue + training + cocktail) for all other participants

ABOUT MATWIN

MATWIN " Maturation & Accelerating Translation With INdustry " is a national open innovation program in oncology. It is based on a partnership with major international pharmaceutical and diagnostic companies that are keen to identify projects with development potential in oncology in order to accelerate the prospects of treatment or diagnosis for patients (AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genomic Health, GlaxoSmithKline, Janssen, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi).

The objectives of MATWIN are to :

- to identify and select innovative research projects with high transfer potential (expertise)

- accompany these projects to optimize their industrial attractiveness (coaching);

- to expose these projects to industrial scrutiny in order to accelerate their development for the benefit of patients (partnership).

For more information: www.matwin.fr

CONTACTS

MATWIN - stephanie.dhont@matwin.fr - Tel: 05 35 54 19 36

CANCER CAMPUS - nouzha.mohellibi@cancer-campus.com - Tel : 01 41 65 90 14

138 views0 comments

Comments


bottom of page